Experimental and clinical studies consistently demonstrate that high SUA can impair insulin signalling in the liver, skeletal muscle, and adipose tissue, while metabolic disturbances such as obesity and hyperinsulinemia further exacerbate hyperuricemia, creating a reinforcing pathological cycle. Here, INS is linked to hyperuricemia.